FRM
PRQR icon

Fox Run Management’s ProQR Therapeutics PRQR Stock Holding History

Fox Run Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-14,361
Closed -$95K – 416
2021
Q1 		$95K Buy
+14,361
New +$73.4K 0.17% 188

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Fox Run Management's PRQR Position: Q2 2021 in Review

Fox Run Management sold out of ProQR Therapeutics (PRQR) in Q2 2021, closing a stake of 14,361 shares — an estimated $95K sold.

Fox Run Management first reported a position in PRQR in Q1 2021 and held it in 1 quarter. The position peaked at $95K in Q1 2021. 63 funds tracked by Wall St. Rank hold PRQR as of Q2 2021.

  • Fox Run Management reported no remaining ProQR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Fox Run Management sold 14,361 ProQR Therapeutics shares in Q2 2021, an estimated $95K.
  • Fox Run Management first reported a position in ProQR Therapeutics in Q1 2021 and held it in 1 quarter.
  • Fox Run Management's ProQR Therapeutics position peaked at $95K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2021.

Based on Fox Run Management's 13F filing for Q2 2021, filed 5 Aug 2021.